Analysis of information sources in references of the Wikipedia article "مضاد اكتئاب" in Arabic language version.
{{استشهاد بكتاب}}
: الوسيط غير المعروف |name-list-format=
تم تجاهله يقترح استخدام |name-list-style=
(مساعدة)In network meta-analysis, tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), a serotonin-noradrenaline reuptake inhibitor (SNRI; venlafaxine), a low-dose serotonin antagonist and reuptake inhibitor (SARI; trazodone) and hypericum extracts were found to be significantly superior to placebo, with estimated odds ratios between 1.69 and 2.03. There were no statistically significant differences between these drug classes. Reversible inhibitors of monoaminoxidase A (rMAO-As) and hypericum extracts were associated with significantly fewer dropouts because of adverse effects compared with TCAs, SSRIs, the SNRI, a noradrenaline reuptake inhibitor (NRI), and noradrenergic and specific serotonergic antidepressant agents (NaSSAs). ... TCAs and SSRIs have the most solid evidence base. Further agents (hypericum, rMAO-As, SNRI, NRI, NaSSAs, SARI) showed some positive results, but limitations of the currently available evidence makes a clear recommendation on their place in clinical practice difficult.
{{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: وصلة دوي غير نشطة منذ 2017 (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: أسماء متعددة: قائمة المؤلفين (link){{استشهاد ويب}}
: استعمال الخط المائل أو الغليظ غير مسموح: |ناشر=
(مساعدة)In network meta-analysis, tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), a serotonin-noradrenaline reuptake inhibitor (SNRI; venlafaxine), a low-dose serotonin antagonist and reuptake inhibitor (SARI; trazodone) and hypericum extracts were found to be significantly superior to placebo, with estimated odds ratios between 1.69 and 2.03. There were no statistically significant differences between these drug classes. Reversible inhibitors of monoaminoxidase A (rMAO-As) and hypericum extracts were associated with significantly fewer dropouts because of adverse effects compared with TCAs, SSRIs, the SNRI, a noradrenaline reuptake inhibitor (NRI), and noradrenergic and specific serotonergic antidepressant agents (NaSSAs). ... TCAs and SSRIs have the most solid evidence base. Further agents (hypericum, rMAO-As, SNRI, NRI, NaSSAs, SARI) showed some positive results, but limitations of the currently available evidence makes a clear recommendation on their place in clinical practice difficult.
{{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: وصلة دوي غير نشطة منذ 2017 (link)In network meta-analysis, tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), a serotonin-noradrenaline reuptake inhibitor (SNRI; venlafaxine), a low-dose serotonin antagonist and reuptake inhibitor (SARI; trazodone) and hypericum extracts were found to be significantly superior to placebo, with estimated odds ratios between 1.69 and 2.03. There were no statistically significant differences between these drug classes. Reversible inhibitors of monoaminoxidase A (rMAO-As) and hypericum extracts were associated with significantly fewer dropouts because of adverse effects compared with TCAs, SSRIs, the SNRI, a noradrenaline reuptake inhibitor (NRI), and noradrenergic and specific serotonergic antidepressant agents (NaSSAs). ... TCAs and SSRIs have the most solid evidence base. Further agents (hypericum, rMAO-As, SNRI, NRI, NaSSAs, SARI) showed some positive results, but limitations of the currently available evidence makes a clear recommendation on their place in clinical practice difficult.
{{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد بدورية محكمة}}
: صيانة الاستشهاد: دوي مجاني غير معلم (link){{استشهاد ويب}}
: استعمال الخط المائل أو الغليظ غير مسموح: |ناشر=
(مساعدة)